Brown Advisory Inc. grew its stake in shares of Zoetis Inc (NYSE:ZTS) by 2.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,207,114 shares of the company’s stock after buying an additional 149,095 shares during the quarter. Zoetis comprises 1.6% of Brown Advisory Inc.’s holdings, making the stock its 7th biggest position. Brown Advisory Inc.’s holdings in Zoetis were worth $519,200,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds also recently added to or reduced their stakes in ZTS. Harel Insurance Investments & Financial Services Ltd. bought a new stake in shares of Zoetis during the 4th quarter worth about $108,000. Steward Partners Investment Advisory LLC bought a new stake in shares of Zoetis during the 3rd quarter worth about $114,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its position in shares of Zoetis by 251.9% during the 3rd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock worth $121,000 after buying an additional 1,360 shares in the last quarter. Shine Investment Advisory Services Inc. raised its position in shares of Zoetis by 86.5% during the 3rd quarter. Shine Investment Advisory Services Inc. now owns 2,242 shares of the company’s stock worth $143,000 after buying an additional 1,040 shares in the last quarter. Finally, Advisory Services Network LLC raised its position in shares of Zoetis by 42.4% during the 4th quarter. Advisory Services Network LLC now owns 2,423 shares of the company’s stock worth $175,000 after buying an additional 721 shares in the last quarter. Institutional investors own 94.18% of the company’s stock.
A number of research firms have commented on ZTS. Barclays set a $77.00 price target on shares of Zoetis and gave the stock a “hold” rating in a research report on Saturday. Deutsche Bank boosted their target price on shares of Zoetis from $76.00 to $78.00 and gave the stock a “hold” rating in a report on Friday, February 16th. Piper Jaffray Companies set a $88.00 target price on shares of Zoetis and gave the stock a “buy” rating in a report on Friday, February 16th. Stifel Nicolaus reiterated a “buy” rating and issued a $86.00 target price (up from $84.00) on shares of Zoetis in a report on Friday, February 16th. Finally, Bank of America boosted their target price on shares of Zoetis from $80.00 to $87.00 and gave the stock a “buy” rating in a report on Friday, February 16th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $79.83.
Zoetis Inc (NYSE ZTS) opened at $80.35 on Wednesday. The firm has a market cap of $39,600.00, a P/E ratio of 36.86, a PEG ratio of 1.80 and a beta of 1.07. The company has a quick ratio of 2.55, a current ratio of 3.85 and a debt-to-equity ratio of 2.77. Zoetis Inc has a 1 year low of $52.25 and a 1 year high of $81.47.
Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 15th. The company reported $0.69 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.03. The business had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.40 billion. Zoetis had a net margin of 16.28% and a return on equity of 65.96%. The firm’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period last year, the firm posted $0.47 earnings per share. research analysts predict that Zoetis Inc will post 3.02 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, April 20th will be given a $0.126 dividend. This represents a $0.50 annualized dividend and a dividend yield of 0.63%. The ex-dividend date of this dividend is Thursday, April 19th. Zoetis’s dividend payout ratio (DPR) is currently 22.94%.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.